Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production

Clinical and Vaccine Immunology : CVI
Daniela M FerreiraEliane N Miyaji

Abstract

We have previously shown that DNA immunization with PspA (pneumococcal surface protein A) DNA is able to elicit protection comparable to that elicited by immunization with PspA protein (with alum as adjuvant), even though the antibody levels elicited by DNA immunization are lower than those elicited by immunization with the protein. This work aims at characterizing the ability of sera to bind to the pneumococcal surface and to mediate complement deposition, using BALB/c wild-type and interleukin-4 knockout mice. We observed that higher anti-PspA levels correlated with intense antibody binding to the pneumococcal surface, while elevated complement deposition was observed with sera that presented balanced immunoglobulin G1 (IgG1)/IgG2a ratios, such as those from DNA-immunized mice. Furthermore, we demonstrated that gamma interferon and tumor necrosis factor alpha were strongly induced after intraperitoneal pneumococcal challenge only in mice immunized with the DNA vaccine. We therefore postulate that although both DNA and recombinant protein immunizations are able to protect mice against intraperitoneal pneumococcal challenge, an optimized response would be achieved by using a DNA vaccine and other strategies capable of inducing ...Continue Reading

References

Jul 1, 1997·Infection and Immunity·J B Rubins, C Pomeroy
Oct 28, 1998·Proceedings of the National Academy of Sciences of the United States of America·S HaraguchiR A Good
Oct 31, 2000·Scandinavian Journal of Infectious Diseases·P EjstrudH T Sørensen
Feb 21, 2002·Infection and Immunity·Alison R KerrTim J Mitchell
Mar 23, 2005·Proceedings of the National Academy of Sciences of the United States of America·Richard MalleyMarc Lipsitch
Mar 15, 2006·Journal of Medical Microbiology·Daniela M FerreiraLuciana C C Leite
Sep 29, 2006·Cellular Microbiology·Barbara AlbigerBirgitta Henriques-Normark
Feb 13, 2007·Diagnostic Microbiology and Infectious Disease·Christiane NicolettiAnna S Levin

❮ Previous
Next ❯

Citations

Sep 6, 2008·Canadian Journal of Microbiology·Andréa da Silva Ramos RochaOdir Antônio Dellagostin
Aug 22, 2012·Canadian Journal of Microbiology·Helton Fernandes AraújoSophie Yvette Leclercq
Jan 29, 2014·The Journal of Infectious Diseases·Andrea BischofUlrich A Maus
Dec 28, 2012·Cellular and Molecular Life Sciences : CMLS·Eliane Namie MiyajiPaulo Lee Ho
Jul 14, 2010·Expert Review of Vaccines·Mariana IngolottiDavid B Weiner
Jun 9, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Lin XuSidong Xiong
Dec 7, 2017·Memórias do Instituto Oswaldo Cruz·Carlos Eduardo Pouey da CunhaFabricio Rochedo Conceição
May 9, 2014·Clinical and Vaccine Immunology : CVI·Carolina Salcedo-RivillasMaria Leonor S Oliveira
Jun 30, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yoshiko FukuyamaKohtaro Fujihashi
Dec 12, 2017·The Laryngoscope·Hiromi NaganoKohtaro Fujihashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.